Cargando…

Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses

Immunotherapy strategies targeting the programmed cell death ligand 1 (PD-L1)/programmed cell death 1 (PD-1) pathway in clinical treatments have achieved remarkable success in treating multiple types of cancer. However, owing to the heterogeneity of tumors and individual immune systems, PD-L1/PD-1 b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Xi, Pan, Xiaohui, Zhang, Wenxin, Guo, Hongjie, Cheng, Shuyuan, He, Qiaojun, Yang, Bo, Ding, Ling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276686/ https://www.ncbi.nlm.nih.gov/pubmed/32528824 http://dx.doi.org/10.1016/j.apsb.2019.09.006

Ejemplares similares

Mevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA
por: Zhang, Wenxin, et al.
Publicado: (2023)

Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling
por: Ding, Ling, et al.
Publicado: (2023)

Dihydropyridine Calcium Channel Blockers Suppress the Transcription of PD-L1 by Inhibiting the Activation of STAT1
por: Pan, Xiaohui, et al.
Publicado: (2021)

Bafetinib Suppresses the Transcription of PD-L1 Through c-Myc in Lung Cancer
por: Chen, Xi, et al.
Publicado: (2022)

Epigenetic Modification of PD-1/PD-L1-Mediated Cancer Immunotherapy against Melanoma
por: Nanamori, Hikaru, et al.
Publicado: (2022)

New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1
por: Villanueva, Nicolas, et al.
Publicado: (2018)

PGAM1 Inhibition Promotes HCC Ferroptosis and Synergizes with Anti‐PD‐1 Immunotherapy
por: Zheng, Yimin, et al.
Publicado: (2023)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer
por: Ding, Naiqing, et al.
Publicado: (2019)

CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma
por: Guo, Xiao-Jun, et al.
Publicado: (2021)

The regulatory and modulatory roles of TRP family channels in malignant tumors and relevant therapeutic strategies
por: Zhong, Tiecheng, et al.
Publicado: (2022)

Systematic investigation of chemo-immunotherapy synergism to shift anti-PD-1 resistance in cancer
por: Wang, Yue, et al.
Publicado: (2023)

Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy
por: Ding, Peng, et al.
Publicado: (2022)

The impact of lipids on the cancer–immunity cycle and strategies for modulating lipid metabolism to improve cancer immunotherapy
por: Zheng, Mingming, et al.
Publicado: (2023)

Targeting PD-1/PD-L1 interactions for cancer immunotherapy
por: Zitvogel, Laurence, et al.
Publicado: (2012)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities
por: Dai, Mengyuan, et al.
Publicado: (2022)

Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
por: Ai, Leilei, et al.
Publicado: (2020)

PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma
por: Hirata-Nozaki, Yui, et al.
Publicado: (2019)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma
por: Huang, Fu-xue, et al.
Publicado: (2022)

Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1
por: Chardin, Laure, et al.
Publicado: (2021)

Correction: New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities
por: Dai, Mengyuan, et al.
Publicado: (2022)

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
por: Tang, Fei, et al.
Publicado: (2018)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy
por: Jiang, Wenxiao, et al.
Publicado: (2021)

Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer
por: Ge, Yanjun, et al.
Publicado: (2022)

IFNAR blockade synergizes with oncolytic VSV to prevent virus-mediated PD-L1 expression and promote antitumor T cell activity
por: El-Sayes, Nader, et al.
Publicado: (2022)

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
por: Bevins, Nicholas J., et al.
Publicado: (2022)

Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy
por: Shen, Wenhui, et al.
Publicado: (2023)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade
por: Zhang, Min, et al.
Publicado: (2019)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy
por: Escors, David, et al.
Publicado: (2022)

Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker
por: Wang, Zhengyi, et al.
Publicado: (2020)

Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors
por: Thuru, Xavier, et al.
Publicado: (2022)

A combination of PD-1/PD-L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy
por: Kong, Xianbin, et al.
Publicado: (2021)

Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti–PD-1/PD-L1 Agents
por: Assi, Hikmat H., et al.
Publicado: (2021)

Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal
por: Wang, Zhenqing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_th32980rq78bpvnbonrojmero8